Page 19 - AN-3-3

Advanced Neurology Alzheimer’s and Parkinson’s disease rodent models

Funding doi: 10.3389/fpubh.2021.776847

This study was funded by the Coordination for the 4. Denver P, McClean P. Distinguishing normal brain aging
Improvement of Higher Education Personnel (CAPES, from the development of Alzheimer’s disease: Inflammation,
insulin signaling and cognition. Neural Regen Res.
Brazil - Finance Code 001), the São Paulo State Research 2018;13(10):1719.
Foundation (FAPESP, Brazil, contracts #2018/07366-4 and
#2022/14820-9), and The National Council for Scientific doi: 10.4103/1673-5374.238608
and Technological Development (CNPq, Brazil). Ana 5. Arosio P. Biophysical aspects of Alzheimer’s disease:
Flávia F. Ferreira received a PhD fellowship from FAPESP Implications for pharmaceutical sciences : Theme: Drug
under Grant Agreements #2020/02109-3 and #2022/14846- discovery, development and delivery in Alzheimer’s
8. Livia M. Lemuchi, Maria E. Bianchetti, and Nicole M. disease guest editor: Davide Brambilla. Pharm Res.
Kamidai received a scientific initiation undergraduate 2017;34(12):2628-2636.
fellowship from FAPESP under Grant Agreements doi: 10.1007/s11095-017-2266-4
#2023/05573-0, #2023/05618-4, and #2023/02355-2. 6. DeTure MA, Dickson DW. The neuropathological diagnosis

Conflict of interest of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32.
doi: 10.1186/s13024-019-0333-5
The authors declare they have no competing interests.
7. Xu YJ, Au NPB, Ma CHE. Functional and phenotypic
Author contributions diversity of microglia: Implication for microglia-based
therapies for Alzheimer’s disease. Front Aging Neurosci.
Conceptualization: Ana Flávia F. Ferreira 2022;14:896852.
Writing – original draft: Ana Flávia F. Ferreira, Livia M. doi: 10.3389/fnagi.2022.896852
Lemuchi, Maria E. Bianchetti, Marina Meira, Nicole
M. Kamidai, Livia M. Kilinsky 8. Murayama S, Saito Y. Neuropathological diagnostic criteria
Writing – review & editing: Ana Flávia F. Ferreira, Marina for Alzheimer’s disease. Neuropathology. 2004;24(3):254-260.
Meira, Luiz R. G. Britto doi: 10.1111/j.1440-1789.2004.00571.x
Ethics approval and consent to participate 9. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat
Rev Dis Prim. 2017;3:17013.
Not applicable. doi: 10.1038/nrdp.2017.13

Consent for publication 10. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression
and mortality. Neurology. 1967;17(5):427-442.
Not applicable.
doi: 10.1212/wnl.17.5.427
Availability of data 11. Poewe W. Non-motor symptoms in Parkinson’s disease. Eur
J Neurol. 2008;15 Suppl 1:14-20.
Data are available upon reasonable request.
doi: 10.1111/j.1468-1331.2008.02056.x
References 12. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, et al.

1. United Nations. World Social Report 2023: Leaving No One Pathophysiology of the basal ganglia in Parkinson’s disease.
Behind in an Ageing World. (Department of Economic Trends Neurosci. 2000;23(10 Suppl):S8-S19.
and Social Affairs (DESA) PD, ed). United Nations; 2023. doi: 10.1016/s1471-1931(00)00028-8
Available from: https://social.desa.un.org/sites/default/
files/publications/2023-02/worldsocialreport2023.pdf [Last 13. Kinter LB, DeHaven R, Johnson DK, DeGeorge JJ.
accessedon 2024 Apr . A brief history of use of animals in biomedical research
14
and perspective on non-animal alternatives. ILAR J.
2. Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and 2021;62(1-2):7-16.
national burden of Alzheimer’s disease and other dementias,
1990–2016: A systematic analysis for the Global Burden of doi: 10.1093/ilar/ilab020
Disease Study 2016. Lancet Neurol. 2019;18(1):88-106. 14. Bryda EC. The mighty mouse: The impact of rodents on
doi: 10.1016/S1474-4422(18)30403-4 advances in biomedical research. Mo Med. 2013;110(3):207-211.
3. Ou Z, Pan J, Tang S, et al. Global trends in the incidence, 15. Dawson TM, Golde TE, Lagier-Tourenne C. Animal
prevalence, and years lived with disability of Parkinson’s models of neurodegenerative diseases. Nat Neurosci.
disease in 204 countries/territories from 1990 to 2019. Front 2018;21(10):1370-1379.
Public Health. 2021;9:776847. doi: 10.1038/s41593-018-0236-8

Volume 3 Issue 3 (2024) 13 doi: 10.36922/an.2903